MUC1 and lung carcinoma: Systemic response and its positive correlation with clinical outcome have been observed in colorectal cancer (antibodies against carcinoembryonic antigen), pancreas cancer [antibodies against mucin 1 (MUC1)], anaplastic large cell lymphoma (antibodies against anaplastic lymphoma kinase), and lung cancer (antibodies against zinc-binding α2-glycoprotein-1) (27).